Autoimmune Disorder, Primary Sjögren's Syndrome, Rheumatoid Arthritis, Systemic Lupus Erythematosus
Conditions
Brief summary
The purpose of this study is to evaluate the safety and effectiveness of treatment with branebrutinib treatment in participants with active systemic Lupus Erythematosus (SLE) or Primary Sjögren's Syndrome (pSS), or branebrutinib treatment followed by open-label abatacept treatment in study participants with active Rheumatoid Arthritis (RA).
Interventions
DRUGbranebrutinib
Specified dose on specified days
DRUGabatacept
Specified dose on specified days
DRUGbranebrutinib placebo
Specified dose on specified days
Sponsors
Bristol-Myers Squibb
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
double-blind
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
Sub-study for Systemic Lupus Erythematosus (SLE) * Active SLE as defined by the Systemic Lupus Erythematosus International Collaborating Clinics (SLICC) classification * Diagnosed with SLE more than 24 weeks before screening visit Sub-study for primary Sjögren's Syndrome (pSS) * Moderate to severe pSS, meeting ACR-EULAR classification criteria Sub-study for active Rheumatoid Arthritis (RA) * Moderate to severe adult-onset RA * ACR global functional status class I to III Women and men must agree to follow instructions for methods of contraception.
Exclusion criteria
Sub-study for SLE * Certain other autoimmune diseases and overlap syndromes Sub-study for pSS * Certain other immune-mediated diseases, active fibromyalgia, or other medical conditions Sub-study for RA * Diagnosis with juvenile arthritis or idiopathic arthritis before age 16 For all sub-studies: * History of any significant drug allergy * Active infection, significant concurrent medical condition, or clinically significant abnormalities Other protocol defined inclusion/
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The Percent of Participants With mCLASI Response at Week 24 and Corticosteroid (CS) < 10 mg/Day at Week 20 and Week 24 - SLE | Week 24 | mCLASI response is defined as a decrease of ≥ 50% from baseline mCLASI activity score, in participants with a baseline mCLASI activity score ≥ 10, at Week 24. Baseline values are defined as the last nonmissing value prior to the first dose of study treatment. To be considered as meeting the second criterion, the CS (prednisone or equivalent) dose had to remain stable and ≤ 10 mg from Week 16 until Week 24. The modified CLASI (mCLASI) is defined as the activity portions of CLASI that describe skin erythema and scale/hypertrophy and inflammation of the scalp. The percentage of patients who entered the study with a positive mCLASI activity score (≥ 10) and who achieved a ≥ 50% decrease from baseline at Week 24 is considered to likely represent a clinically meaningful improvement. The scores are calculated by simple addition based on the extent of the symptoms. mCLASI: Modified Cutaneous Lupus Erythematosus Disease Area and Severity Index |
| The Percent of Participants With Composite Response at Week 24 - pSS | Week 24 | Composite response is defined as the percent of participants with at least 3 of the following at Week 24: * Decrease of ≥ 1 point or 15% from baseline in the ESSPRI Total Score * Decrease of ≥ 3 points from baseline in ESSDAI score * Decrease of ≥ 25% from baseline in ocular staining score, or if normal score at baseline no change to abnormal * Increase of ≥ 25% from baseline in stimulated salivary flow * Improvement in one or more serological markers (rheumatoid factor (RF), immunoglobulin G protein (IgG), complement C3 or C4, cryoglobulin). |
| Percent of Participants With ACR50 Response at Week 12 Compared to Baseline - RA | Week 12 | ACR50 response is defined as both improvement of 50% in the number of tender and swollen joints and a 50% improvement in 3 of the following 5 criteria: * Subject global assessment (SGA) * Physician global assessment (PGA) * Functional ability measure * Pain visual analog scale (VAS) * Erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP). Baseline values are defined as the last nonmissing value prior to the first dose of study treatment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in DAS28-ESR at Week 12 - RA | Week 12 | The Disease Activity Score Erythrocyte Sedimentation Rate - DAS28ESR is a composite outcome assessment that measures: 1. How many joints in the hands, wrists, elbows, shoulders, and knees are swollen and/or tender over a total of 28 2. ESR in the blood to measure the degree of inflammation 3. SGA of disease activity DAS28-ESR scores range from 1.0 to 9.4, where lower scores indicate less disease activity. The results are combined to produce the DAS28-ESR score, which correlates with the extent of disease activity: \< 2.6: Disease remission 2.6 - 3.2: Low disease activity 3.2 - 5.1: Moderate disease activity \> 5.1: High disease activity A negative change from baseline in DAS28-ESR indicates an improvement. Baseline values are defined as the last nonmissing value prior to the first dose of study treatment. |
| Change From Baseline in SDAI at Week 12- RA | Week 12 | The Simplified Disease Activity Index (SDAI) is the sum of the tender joint score (range 0 to 28), the swollen joint score (range 0 to 28), the subject global assessment (SGA) of disease activity (range 0 to 10 in increments of 0.5), the PGA of disease activity (range 0 to 10 in increments of 0.5), and C-reactive protein (CRP) test result. Baseline values are defined as the last nonmissing value prior to the first dose of study treatment. A SDAI score ranges from 0 (disease remission) to 86 (high disease activity). |
| Change From Baseline in SLEDAI-2K Score at Week 24 - SLE | Week 24 | The SLEDAI-2K is a global index providing a total score of overall disease activity ranging from 0 to 105, with higher scores representing more active disease. The SLEDAI index includes 24 items divided into 9 organ systems: neurological, musculoskeletal, renal, mucocutaneous, general, heart, respiratory, vascular, and hematological. Each item is scored based on the severity of the symptom or finding, with higher scores indicating more severe disease activity. The weighted scores for each item range from 0 to 8. To calculate the SLEDAI-2K score, the scores for each of the 24 items are added together. Baseline values are defined as the last nonmissing value prior to the first dose of study treatment. |
| Percent of Participants With ACR20 Response Compared to Baseline at Week 12 - RA | Week 12 | ACR20 defined as both improvement of 20% in the number of tender and swollen joints and a 20% improvement in 3 of the following 5 criteria: * Subject global assessment (SGA) * Physician global assessment (PGA) * Functional ability measure * Pain visual analog scale (VAS) * Erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP). Baseline values are defined as the last nonmissing value prior to the first dose of study treatment. |
| Percent of Participants With ACR70 Response Compared to Baseline at Week 12 - RA | Week 12 | ACR70 is defined as both improvement of 70% in the number of tender and swollen joints and a 70% improvement in 3 of the following 5 criteria: * Subject global assessment (SGA) * Physician global assessment (PGA) * Functional ability measure * Pain visual analog scale (VAS) * Erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP). Baseline values are defined as the last nonmissing value prior to the first dose of study treatment. |
| Change From Baseline in CDAI at Week 12 - RA | Week 12 | The Clinical Disease Activity Index (CDAI) is the sum of the tender joint score (range 0 to 28), the swollen joint score (range 0 to 28), the SGA of disease activity (range 0 to 10 in increments of 0.5), and the PGA of disease activity (range 0 to 10 in increments of 0.5). Baseline values are defined as the last nonmissing value prior to the first dose of study treatment. A CDAI score ranges from 0 to 76. The interpretation of CDAI is as follows: 0.0 - 2.8: Disease remission 2.9 - 10.0: Low disease activity (LDA) 10.1 - 22.0: Moderate disease activity 22.1 - 76.0: High disease activity |
| Percent of Participants With BICLA Response at Week 24 - SLE | Week 24 | BILAG-based composite lupus assessment (BICLA) response is defined as: 1. At least one gradation of improvement in baseline BILAG scores in all body systems with moderate or severe disease activity at entry 2. No new BILAG A or more than one new BILAG B scores 3. No worsening of total SLEDAI score from baseline 4. No significant deterioration (\< 10%) in PGA and 5. No treatment failure (initiation of nonprotocol treatment). BILAG scores: A (severe disease), B (moderate), C (mild), or D (no activity). Baseline values are defined as the last nonmissing value prior to the first dose of study treatment. |
| Change From Baseline in DAS28-CRP at Week 12 - RA | Week 12 | The Disease Activity Score-28-C-Reactive Protein (DAS28CRP) is a composite outcome assessment that measures: 1) How many joints in the hands, wrists, elbows, shoulders, and knees are swollen and/or tender over a total of 28, 2) CRP in the blood to measure the degree of inflammation, and 3) SGA of disease activity. DAS28-CRP scores range from 1.0 to 9.4, where lower scores indicate less disease activity. The results are combined to produce the DAS28-CRP score, which correlates with the extent of disease activity: \< 2.6: Disease remission 2.6 - 3.2: Low disease activity 3.2 - 5.1: Moderate disease activity \> 5.1: High disease activity A negative change from baseline in DAS28-CRP indicates an improvement. Baseline values are defined as the last nonmissing value prior to the first dose of study treatment. |
Countries
Argentina, Belgium, France, Germany, Mexico, Netherlands, Poland, Spain, United Kingdom, United States
Participant flow
Pre-assignment details
Participants were enrolled concurrently for the RA, SLE, and pSS sub-studies.
Participants by arm
| Arm | Count |
|---|---|
| SLE- Placebo Participants with systemic lupus erythematosus (SLE) receive placebo once daily (QD) during a 24-week double-blind placebo-controlled treatment period. | 5 |
| SLE- Branebrutinib Participants with systemic lupus erythematosus (SLE) receive branebrutinib 9mg once daily (QD) during a 24-week double-blind placebo-controlled treatment period. | 15 |
| pSS- Placebo Participants with primary Sjögren's syndrome (pSS) receive placebo once daily (QD) during a 24-week double-blind placebo-controlled treatment period. | 4 |
| pSS- Branebrutinib Participants with primary Sjögren's syndrome (pSS) receive branebrutinib 9mg once daily (QD) during a 24-week double-blind placebo-controlled treatment period. | 10 |
| RA- Placebo Participants with rheumatoid arthritis (RA) receive placebo once daily (QD) during a 12-week double-blind placebo-controlled treatment period, followed by an additional 12 weeks of treatment with open-label abatacept. | 21 |
| RA- Branebrutinib Participants with rheumatoid arthritis (RA) receive branebrutinib 9mg once daily (QD) during a 12-week double-blind placebo-controlled treatment period, followed by an additional 12 weeks of treatment with open-label abatacept. | 64 |
| Total | 119 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 |
|---|---|---|---|---|---|---|---|
| Overall Study | Adverse Event | 1 | 1 | 0 | 0 | 0 | 2 |
| Overall Study | Lack of Efficacy | 0 | 1 | 0 | 0 | 1 | 1 |
| Overall Study | Lost to Follow-up | 0 | 0 | 0 | 0 | 0 | 1 |
| Overall Study | Other reasons | 0 | 0 | 0 | 0 | 0 | 1 |
| Overall Study | Study terminated by sponsor | 1 | 2 | 0 | 1 | 0 | 0 |
| Overall Study | Withdrawal by Subject | 0 | 0 | 0 | 0 | 0 | 1 |
Baseline characteristics
| Characteristic | SLE- Branebrutinib | SLE- Placebo | Total | RA- Branebrutinib | RA- Placebo | pSS- Branebrutinib | pSS- Placebo |
|---|---|---|---|---|---|---|---|
| Age, Continuous | 44.2 Years STANDARD_DEVIATION 12.91 | 47.6 Years STANDARD_DEVIATION 10.99 | 48.2 Years STANDARD_DEVIATION 11.68 | 50.1 Years STANDARD_DEVIATION 11.62 | 46.0 Years STANDARD_DEVIATION 12.95 | 46.6 Years STANDARD_DEVIATION 9.28 | 47.8 Years STANDARD_DEVIATION 4.19 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 9 Participants | 3 Participants | 21 Participants | 7 Participants | 1 Participants | 1 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 6 Participants | 2 Participants | 97 Participants | 57 Participants | 20 Participants | 8 Participants | 4 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants |
| Race/Ethnicity, Customized Asian - Non-Japanese American Indian or Alaska Native | 6 Participants | 2 Participants | 8 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Asian - Non-Japanese Asian - Non-Japanese | 0 Participants | 0 Participants | 2 Participants | 2 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Asian - Non-Japanese Black or African American | 3 Participants | 1 Participants | 6 Participants | 2 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Asian - Non-Japanese Not Reported | 0 Participants | 0 Participants | 2 Participants | 1 Participants | 0 Participants | 1 Participants | 0 Participants |
| Race/Ethnicity, Customized Asian - Non-Japanese White | 6 Participants | 2 Participants | 101 Participants | 59 Participants | 21 Participants | 9 Participants | 4 Participants |
| Sex: Female, Male Female | 14 Participants | 5 Participants | 93 Participants | 45 Participants | 18 Participants | 7 Participants | 4 Participants |
| Sex: Female, Male Male | 1 Participants | 0 Participants | 26 Participants | 19 Participants | 3 Participants | 3 Participants | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk |
|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 5 | 0 / 15 | 0 / 4 | 0 / 10 | 0 / 21 | 0 / 64 | 0 / 81 |
| other Total, other adverse events | 4 / 5 | 14 / 15 | 4 / 4 | 8 / 10 | 6 / 21 | 13 / 64 | 5 / 81 |
| serious Total, serious adverse events | 0 / 5 | 0 / 15 | 0 / 4 | 0 / 10 | 0 / 21 | 0 / 64 | 0 / 81 |
Outcome results
Primary
Percent of Participants With ACR50 Response at Week 12 Compared to Baseline - RA
ACR50 response is defined as both improvement of 50% in the number of tender and swollen joints and a 50% improvement in 3 of the following 5 criteria: * Subject global assessment (SGA) * Physician global assessment (PGA) * Functional ability measure * Pain visual analog scale (VAS) * Erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP). Baseline values are defined as the last nonmissing value prior to the first dose of study treatment.
Time frame: Week 12
Population: All Treated Participants (Prespecified for participants in the RA cohort only).
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| SLE- Placebo | Percent of Participants With ACR50 Response at Week 12 Compared to Baseline - RA | 33.3 Percent of Participants |
| SLE- Branebrutinib | Percent of Participants With ACR50 Response at Week 12 Compared to Baseline - RA | 18.8 Percent of Participants |
95% CI: [-36.9, 7.7]
p-value: 0.163995% CI: [0.15, 1.39]Chi-squared
Primary
The Percent of Participants With Composite Response at Week 24 - pSS
Composite response is defined as the percent of participants with at least 3 of the following at Week 24: * Decrease of ≥ 1 point or 15% from baseline in the ESSPRI Total Score * Decrease of ≥ 3 points from baseline in ESSDAI score * Decrease of ≥ 25% from baseline in ocular staining score, or if normal score at baseline no change to abnormal * Increase of ≥ 25% from baseline in stimulated salivary flow * Improvement in one or more serological markers (rheumatoid factor (RF), immunoglobulin G protein (IgG), complement C3 or C4, cryoglobulin).
Time frame: Week 24
Population: All Treated Participants (Prespecified for participants in the pSS cohort only).
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| SLE- Placebo | The Percent of Participants With Composite Response at Week 24 - pSS | 25 Percent of Participants |
| SLE- Branebrutinib | The Percent of Participants With Composite Response at Week 24 - pSS | 10 Percent of Participants |
95% CI: [-57.1, 33.3]
p-value: 0.59395% CI: [0.02, 10.02]Cochran-Mantel-Haenszel
Primary
The Percent of Participants With mCLASI Response at Week 24 and Corticosteroid (CS) < 10 mg/Day at Week 20 and Week 24 - SLE
mCLASI response is defined as a decrease of ≥ 50% from baseline mCLASI activity score, in participants with a baseline mCLASI activity score ≥ 10, at Week 24. Baseline values are defined as the last nonmissing value prior to the first dose of study treatment. To be considered as meeting the second criterion, the CS (prednisone or equivalent) dose had to remain stable and ≤ 10 mg from Week 16 until Week 24. The modified CLASI (mCLASI) is defined as the activity portions of CLASI that describe skin erythema and scale/hypertrophy and inflammation of the scalp. The percentage of patients who entered the study with a positive mCLASI activity score (≥ 10) and who achieved a ≥ 50% decrease from baseline at Week 24 is considered to likely represent a clinically meaningful improvement. The scores are calculated by simple addition based on the extent of the symptoms. mCLASI: Modified Cutaneous Lupus Erythematosus Disease Area and Severity Index
Time frame: Week 24
Population: All treated participants with a baseline mCLASI activity score ≥ 10 at Week 24 (Prespecified for participants in the SLE cohort only).
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| SLE- Placebo | The Percent of Participants With mCLASI Response at Week 24 and Corticosteroid (CS) < 10 mg/Day at Week 20 and Week 24 - SLE | 60.0 Percentage of participants |
| SLE- Branebrutinib | The Percent of Participants With mCLASI Response at Week 24 and Corticosteroid (CS) < 10 mg/Day at Week 20 and Week 24 - SLE | 33.3 Percentage of participants |
95% CI: [-77.5, 21.9]
p-value: 0.311795% CI: [0.04, 2.73]Cochran-Mantel-Haenszel
Secondary
Change From Baseline in CDAI at Week 12 - RA
The Clinical Disease Activity Index (CDAI) is the sum of the tender joint score (range 0 to 28), the swollen joint score (range 0 to 28), the SGA of disease activity (range 0 to 10 in increments of 0.5), and the PGA of disease activity (range 0 to 10 in increments of 0.5). Baseline values are defined as the last nonmissing value prior to the first dose of study treatment. A CDAI score ranges from 0 to 76. The interpretation of CDAI is as follows: 0.0 - 2.8: Disease remission 2.9 - 10.0: Low disease activity (LDA) 10.1 - 22.0: Moderate disease activity 22.1 - 76.0: High disease activity
Time frame: Week 12
Population: All treated participants with baseline and week 12 measurements (Prespecified for participants in the RA cohort only).
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| SLE- Placebo | Change From Baseline in CDAI at Week 12 - RA | -19.4 Score on a scale | Standard Deviation 12.07 |
| SLE- Branebrutinib | Change From Baseline in CDAI at Week 12 - RA | -18.0 Score on a scale | Standard Deviation 11.01 |
95% CI: [-24.3, -14.1]
95% CI: [-21.4, -15.5]
95% CI: [-5.2, 6.6]
Secondary
Change From Baseline in DAS28-CRP at Week 12 - RA
The Disease Activity Score-28-C-Reactive Protein (DAS28CRP) is a composite outcome assessment that measures: 1) How many joints in the hands, wrists, elbows, shoulders, and knees are swollen and/or tender over a total of 28, 2) CRP in the blood to measure the degree of inflammation, and 3) SGA of disease activity. DAS28-CRP scores range from 1.0 to 9.4, where lower scores indicate less disease activity. The results are combined to produce the DAS28-CRP score, which correlates with the extent of disease activity: \< 2.6: Disease remission 2.6 - 3.2: Low disease activity 3.2 - 5.1: Moderate disease activity \> 5.1: High disease activity A negative change from baseline in DAS28-CRP indicates an improvement. Baseline values are defined as the last nonmissing value prior to the first dose of study treatment.
Time frame: Week 12
Population: All Treated Participants with baseline and week 12 measurements (Prespecified for participants in the RA cohort only).
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| SLE- Placebo | Change From Baseline in DAS28-CRP at Week 12 - RA | -1.615 Score on a scale | Standard Deviation 1.19545 |
| SLE- Branebrutinib | Change From Baseline in DAS28-CRP at Week 12 - RA | -1.542 Score on a scale | Standard Deviation 1.079 |
95% CI: [-2.11, -1.11]
95% CI: [-1.855, -1.28]
95% CI: [-0.534, 0.62]
Secondary
Change From Baseline in DAS28-ESR at Week 12 - RA
The Disease Activity Score Erythrocyte Sedimentation Rate - DAS28ESR is a composite outcome assessment that measures: 1. How many joints in the hands, wrists, elbows, shoulders, and knees are swollen and/or tender over a total of 28 2. ESR in the blood to measure the degree of inflammation 3. SGA of disease activity DAS28-ESR scores range from 1.0 to 9.4, where lower scores indicate less disease activity. The results are combined to produce the DAS28-ESR score, which correlates with the extent of disease activity: \< 2.6: Disease remission 2.6 - 3.2: Low disease activity 3.2 - 5.1: Moderate disease activity \> 5.1: High disease activity A negative change from baseline in DAS28-ESR indicates an improvement. Baseline values are defined as the last nonmissing value prior to the first dose of study treatment.
Time frame: Week 12
Population: All treated participants with baseline and week 12 measurements (Prespecified for participants in the RA cohort only).
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| SLE- Placebo | Change From Baseline in DAS28-ESR at Week 12 - RA | -1.758 Score on a scale | Standard Deviation 1.1932 |
| SLE- Branebrutinib | Change From Baseline in DAS28-ESR at Week 12 - RA | -1.670 Score on a scale | Standard Deviation 1.1487 |
95% CI: [-2.256, -1.226]
95% CI: [-1.998, -1.399]
95% CI: [-0.553, 0.639]
Secondary
Change From Baseline in SDAI at Week 12- RA
The Simplified Disease Activity Index (SDAI) is the sum of the tender joint score (range 0 to 28), the swollen joint score (range 0 to 28), the subject global assessment (SGA) of disease activity (range 0 to 10 in increments of 0.5), the PGA of disease activity (range 0 to 10 in increments of 0.5), and C-reactive protein (CRP) test result. Baseline values are defined as the last nonmissing value prior to the first dose of study treatment. A SDAI score ranges from 0 (disease remission) to 86 (high disease activity).
Time frame: Week 12
Population: All treated participants with baseline and week 12 measurements (Prespecified for participants in the RA cohort only).
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| SLE- Placebo | Change From Baseline in SDAI at Week 12- RA | -19.430 Score on a scale | Standard Deviation 12.589 |
| SLE- Branebrutinib | Change From Baseline in SDAI at Week 12- RA | -18.303 Score on a scale | Standard Deviation 11.5793 |
95% CI: [-24.861, -14.128]
95% CI: [-21.848, -15.686]
95% CI: [-5.463, 6.919]
Secondary
Change From Baseline in SLEDAI-2K Score at Week 24 - SLE
The SLEDAI-2K is a global index providing a total score of overall disease activity ranging from 0 to 105, with higher scores representing more active disease. The SLEDAI index includes 24 items divided into 9 organ systems: neurological, musculoskeletal, renal, mucocutaneous, general, heart, respiratory, vascular, and hematological. Each item is scored based on the severity of the symptom or finding, with higher scores indicating more severe disease activity. The weighted scores for each item range from 0 to 8. To calculate the SLEDAI-2K score, the scores for each of the 24 items are added together. Baseline values are defined as the last nonmissing value prior to the first dose of study treatment.
Time frame: Week 24
Population: All Treated Participants with week 24 measurements (Prespecified for participants in the SLE cohort only).
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| SLE- Placebo | Change From Baseline in SLEDAI-2K Score at Week 24 - SLE | -7.0 Change in score on a scale | Standard Deviation 5.29 |
| SLE- Branebrutinib | Change From Baseline in SLEDAI-2K Score at Week 24 - SLE | -7.0 Change in score on a scale | Standard Deviation 6.54 |
95% CI: [-2.8, 4.9]
95% CI: [-11.5, -5]
95% CI: [-9.3, -5.2]
Secondary
Percent of Participants With ACR20 Response Compared to Baseline at Week 12 - RA
ACR20 defined as both improvement of 20% in the number of tender and swollen joints and a 20% improvement in 3 of the following 5 criteria: * Subject global assessment (SGA) * Physician global assessment (PGA) * Functional ability measure * Pain visual analog scale (VAS) * Erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP). Baseline values are defined as the last nonmissing value prior to the first dose of study treatment.
Time frame: Week 12
Population: All Treated Participants (Prespecified for participants in the RA cohort only).
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| SLE- Placebo | Percent of Participants With ACR20 Response Compared to Baseline at Week 12 - RA | 61.9 Percent of Participants |
| SLE- Branebrutinib | Percent of Participants With ACR20 Response Compared to Baseline at Week 12 - RA | 57.8 Percent of Participants |
95% CI: [-28.1, 19.9]
95% CI: [0.31, 2.32]
Secondary
Percent of Participants With ACR70 Response Compared to Baseline at Week 12 - RA
ACR70 is defined as both improvement of 70% in the number of tender and swollen joints and a 70% improvement in 3 of the following 5 criteria: * Subject global assessment (SGA) * Physician global assessment (PGA) * Functional ability measure * Pain visual analog scale (VAS) * Erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP). Baseline values are defined as the last nonmissing value prior to the first dose of study treatment.
Time frame: Week 12
Population: All Treated Participants (Prespecified for participants in the RA cohort only).
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| SLE- Placebo | Percent of Participants With ACR70 Response Compared to Baseline at Week 12 - RA | 14.3 Percent of Participants |
| SLE- Branebrutinib | Percent of Participants With ACR70 Response Compared to Baseline at Week 12 - RA | 7.8 Percent of Participants |
95% CI: [-22.8, 9.9]
95% CI: [0.11, 2.34]
Secondary
Percent of Participants With BICLA Response at Week 24 - SLE
BILAG-based composite lupus assessment (BICLA) response is defined as: 1. At least one gradation of improvement in baseline BILAG scores in all body systems with moderate or severe disease activity at entry 2. No new BILAG A or more than one new BILAG B scores 3. No worsening of total SLEDAI score from baseline 4. No significant deterioration (\< 10%) in PGA and 5. No treatment failure (initiation of nonprotocol treatment). BILAG scores: A (severe disease), B (moderate), C (mild), or D (no activity). Baseline values are defined as the last nonmissing value prior to the first dose of study treatment.
Time frame: Week 24
Population: All Treated Participants (Prespecified for participants in the SLE cohort only).
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| SLE- Placebo | Percent of Participants With BICLA Response at Week 24 - SLE | 20.0 Percent of participants |
| SLE- Branebrutinib | Percent of Participants With BICLA Response at Week 24 - SLE | 33.3 Percent of participants |
95% CI: [-31.8, 65.2]
95% CI: [0.22, 18.04]